Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Analysis of Population Pharmacokinetic Data

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...

Pharmacokinetic Models: Comparison and Selection Criterion

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.

Pharmacokinetic Models: Overview

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...

Pharmacodynamic Models: Overview

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...

Pharmacokinetic–Pharmacodynamic Relationship: Problems

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.

Hematological oncology·2026

Same author

Cardiac amyloid by cardiovascular magnetic resonance.

BMJ case reports·2025

Same author

Next generation secondary electron detector with energy analysis capability for SEM.

Journal of microscopy·2020

Same author

FOLLICULAR MONITORING: COMPARISON OF TRANSABDOMINAL AND TRANSVAGINAL SONOGRAPHY.

Medical journal, Armed Forces India·2017

Same author

TRANSCUTANEOUS SONOGRAPHIC DIAGNOSIS OF ACHALASIA CARDIA.

Medical journal, Armed Forces India·2017

Search research articles

Related Experiment Video

Updated: Apr 11, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Physiologically based and population PK modeling in optimizing drug development: A predict-learn-confirm analysis.

A Suri¹, S Chapel², C Lu³

¹Clinical Pharmacology, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Clinical Pharmacology and Therapeutics

|June 3, 2015

Summary

Model-based simulations using physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PK) models can optimize drug development for kidney-cleared medications. This approach helps determine the necessity of dedicated renal impairment (RI) studies, potentially streamlining clinical trials.

More Related Videos

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Related Experiment Videos

Last Updated: Apr 11, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Area of Science:

Pharmacokinetics and Drug Metabolism
Clinical Pharmacology
Translational Medicine

Background:

Physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PK) modeling are vital tools in drug development.
Assessing the impact of renal impairment (RI) on drug exposure is crucial for safe and effective drug use.
Current methods for evaluating drugs in renally impaired populations can be resource-intensive.

Purpose of the Study:

To propose and evaluate a model-based methodology for optimizing drug development in patients with renal impairment.
To determine the need for dedicated renal impairment studies using a combined PBPK and population PK approach.
To streamline the inclusion of renally impaired patients in later-phase clinical trials.

Main Methods:

Physiologically based pharmacokinetic (PBPK) modeling was used to simulate the impact of renal impairment on drug exposure.
Classical population pharmacokinetic (PK) modeling of Phase 2/3 data was employed to confirm PBPK predictions.
The methodology was validated using an investigational agent, orteronel, and confirmed with a Phase 1 renal impairment study.

Main Results:

The model-based approach accurately predicted the impact of renal impairment on drug exposure.
The methodology successfully guided dose selection for patients with renal impairment.
Phase 1 study results confirmed the predictive accuracy of the PBPK and population PK models.

Conclusions:

Model-based strategies can effectively assess the need for dedicated renal impairment studies for renally cleared drugs.
This approach may allow for the inclusion of renally impaired patients in Phase 3 trials at appropriate doses.
It offers a potential alternative to full-scale dedicated renal impairment studies, possibly reducing study size or necessity.